Company: SXTPW
Filing Date: 2025-07-07
Form Type: S-1
Source: 0001213900-25-061842
Chunk: 22

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-07-07
Form: S-1
Chunk 22
---
/Botanical Extracts from Australian Chestnut Trees Celgosivir is derived synthetically in a single chemical step from the naturally occurring alkaloid, castanospermine, isolated from extracts of the Australian Chestnut Tree ( Castanospermum australe). When administered to humans or animals, celgosivir is almost completely metabolized to castanospermine, which is the dominant metabolite. Abundant scientific literature has confirmed the antiviral, metabolic, and immunosuppressive properties of castanospermine alkaloids. The Company currently has at least 8.8 kgs of castanospermine in inventory which will be used for additional proof of concept studies.

| 30 | Sorbera et al, Drugs of the Future 2005; 30:545-552. |

| 31 | Low et. al., Lancet ID 2014; 14:706-715. |

| 32 | Watanabe et al, Antiviral Research 2016; 10:e19. |

<div align='center'>6</div>

Strategy

Our general strategy to achieve profitability
and grow shareholder value has three facets: (i) increase sales of Arakoda; (ii) conduct clinical trials to expand the number of patients
who can use Tafenoquine for new indications in the future; and (iii) reposition small molecule therapeutics with good clinical safety
profiles for new indications.

Expansion of U.S. Arakoda Sales

. In
February 2024, we hired Kristen Landon to lead our commercial efforts to reintroduce Arakoda for malaria prevention and conduct new product
planning initiatives in tick-borne disease for babesiosis. We spent the first quarter of 2024 analyzing the current landscape in the malaria
prevention market, conducting primary market research among providers and consumers, and assessing agency partners for a virtual/digital
marketing pilot program. Additionally, we kicked off a market assessment on the babesiosis space including desk top research and qualitative
interviews with Key Opinion Leaders in the Infectious Disease and Lyme Community, a quantitative market survey of 300 prescribing physicians,
a survey of 6,000 U.S. consumers, and an administrative claims study. Thee outputs of these surveys together suggest a substantial market
opportunity.

. A malaria demand study was conducted to assess the attractiveness and acceptability of
the Arakoda product profile and current pricing among health care providers and consumers. The product profile was well received